ストックスクリーナーアプリを入手
1.95
0.52%
0.01
プレマーケット:
1.93
-0.02
-1.03%
Compass Therapeutics Inc (CMPX) 最新ニュース
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update - Investing News Network
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX) - Yahoo Finance
Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary - TradingView
CMPX: Q1 2026 net loss rose to $18.3M; tovecimig advanced with positive BTC data and FDA orphan status - TradingView
Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs - TradingView
CMPX: Tovecimig achieved key clinical milestones in BTC, with strong cash reserves supporting future trials - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Stockholders to Connect - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
CMPX Stock Plunges As Traders Weigh Cancer Trial Fallout - StocksToTrade
CMPX Forecast, Price Target & Analyst Ratings | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
Compass Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Compass Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Anderman Jonathanmoomoo - Moomoo
Compass Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Lerner Neilmoomoo - Moomoo
Compass Therapeutics | DEFA14A: Others - Moomoo
Compass Therapeutics general counsel Jonathan Anderman buys $47,250 in stock - Investing.com India
Compass Therapeutics chief accounting officer buys $28,350 in stock - Investing.com UK
Compass Therapeutics chief accounting officer buys $28,350 in stock By Investing.com - Investing.com India
Compass Therapeutics (NASDAQ: CMPX) CAO buys 15,000 shares - Stock Titan
Compass Therapeutics (CMPX) general counsel buys more company stock - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Compass Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lerner Neil - Moomoo
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics (CMPX) CAO receives 15,000-share equity grant - Stock Titan
CMPX Stock Sinks As Trial Failure Hammers Compass Therapeutics - StocksToTrade
CMPX Stock Plunges As Trial Failure Triggers Downgrade And Probe - StocksToTrade
Compass Therapeutics | DEF 14A: Definitive information statements - Moomoo
[DEF 14A] Compass Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity? - Yahoo Finance
Compass Therapeutics’s stock crashes after OS miss in BTC trial - MSN
[ARS] Compass Therapeutics, Inc. SEC Filing - Stock Titan
Compass Therapeutics (CMPX) Is Down 65.4% After Tovecimig Combo Meets Key BTC Trial EndpointsWhat's Changed - Sahm
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings - Sahm
US Stocks Mixed; Nasdaq Falls Over 100 Points - Sahm
Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $24 - Moomoo
Raymond James Downgrades Compass Therapeutics to Market Perform From Outperform - marketscreener.com
Raymond James downgrades Compass Therapeutics stock rating on trial results - Investing.com Canada
ABL Bio Partner Compass to Pursue FDA Approval Despite Missed Survival Endpoint - Seoul Economic Daily
CMPX - Finviz
Compass drug shows mixed late-stage results, shares slide - The Pharma Letter
Compass Therapeutics stock rating maintained at outperform by Citizens - Investing.com
Compass Therapeutics Inc (CMPX) Stock Price, Quote, News & History - Benzinga
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month LowWhat's Next? - MarketBeat
ABL Bio Partner Compass Meets PFS Endpoint in Bile Duct Cancer Trial - Seoul Economic Daily
Compass Therapeutics boosts PFS in biliary cancer, eyes FDA BLACHOSUNBIZ - Chosunbiz
Compass Therapeutics-Aktie: 64 Prozent weg, weil Statistik zickt! - Finanztrends
S-OS? Compass phase II/III biliary data mixed; ahoy, FDA - BioWorld News
Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS Data - Yahoo Finance
Stifel cuts Compass Therapeutics stock price target on FDA uncertainty By Investing.com - Investing.com Canada
Stifel cuts Compass Therapeutics stock price target on FDA uncertainty - Investing.com
Compass Therapeutics Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design. - Barron's
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies - TipRanks
Compass Therapeutics’ tovecimig meets PFS endpoint in bile duct cancer - Investing.com UK
Compass Therapeutics Faces Investor Claims Investigation - Intellectia AI
Compass Therapeutics Reports Positive Phase 2/3 BTC Results - TipRanks
Compass Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
Compass Therapeutics stock rating reaffirmed at Buy by H.C. Wainwright - Investing.com Canada
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):